Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Profiling Systems Wins $4.1M SBIR to Develop Anthrax-Detection Platform

NEW YORK, Aug. 12 (GenomeWeb News) - Genomic Profiling Systems, a microbial analysis startup based in Bedford, Mass., has received a three-year $4.1 million Phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease to develop a testing platform for rapid diagnosis of anthrax, the company said today.

 

GPS said that the system it is developing, called MultiPath, will enable rapid detection of biowarfare agents on a massive scale. The company expects the platform to have additional applications, including flu testing and detection of pathogens in food.

 

In its Phase I SBIR program, GPS demonstrated that its system "detected bacteria and soluble protein markers at levels that are thousands of times lower than achievable with standard commercial strip tests," Donald Straus, vice president of research and CSO, said in a statement.

 

According to the company's website, MultiPath combines a sandwich immunoassay using high-intensity fluorescent particles with proprietary imaging technology. In its abstract for the Phase II SBIR award, the company said that the test "rapidly detects multiple targets with sensitivities approaching nucleic acid amplification tests but with the cost-effectiveness and user-friendliness of over-the-counter immunoassay 'strip' tests."

 

The grant abstract said that the company's imaging technology "detects individual microparticles rather than the millions of particles required to detect a signal in standard strip tests."

 

GPS said that it will launch its first commercial product, the Growth Direct Test, which detects microbiological contamination in pharmaceutical products, in early 2006.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.